TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at

Research analysts at initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMDGet Free Report) in a research report issued on Saturday. The brokerage set a “hold” rating on the stock.

Separately, Cantor Fitzgerald restated a “neutral” rating on shares of TherapeuticsMD in a report on Thursday, August 17th.

Get Our Latest Research Report on TherapeuticsMD

TherapeuticsMD Stock Performance

Shares of NASDAQ TXMD opened at $3.33 on Friday. TherapeuticsMD has a one year low of $3.25 and a one year high of $8.19. The business has a 50-day moving average price of $3.90 and a two-hundred day moving average price of $3.88.

TherapeuticsMD (NASDAQ:TXMDGet Free Report) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.17). The business had revenue of $0.44 million for the quarter. TherapeuticsMD had a return on equity of 232.35% and a net margin of 61.23%. As a group, analysts anticipate that TherapeuticsMD will post -0.75 earnings per share for the current year.

Hedge Funds Weigh In On TherapeuticsMD

Large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its position in TherapeuticsMD by 727.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,860,361 shares of the company’s stock worth $1,087,000 after buying an additional 2,514,618 shares during the period. Renaissance Technologies LLC grew its stake in shares of TherapeuticsMD by 243.5% in the first quarter. Renaissance Technologies LLC now owns 3,147,599 shares of the company’s stock worth $1,196,000 after acquiring an additional 2,231,301 shares during the last quarter. Royal Bank of Canada increased its position in TherapeuticsMD by 688.1% during the first quarter. Royal Bank of Canada now owns 788,446 shares of the company’s stock worth $299,000 after acquiring an additional 688,399 shares during the period. Tejara Capital Ltd acquired a new position in TherapeuticsMD during the 4th quarter valued at $1,774,000. Finally, Geode Capital Management LLC bought a new stake in TherapeuticsMD in the 4th quarter valued at $374,000. Institutional investors and hedge funds own 28.68% of the company’s stock.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.

Featured Stories

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.